Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide
Journal
Hepatology International
Journal Volume
9
Journal Issue
2
Pages
258-268
Date Issued
2015
Author(s)
Abstract
Background: To correlate between signal parameters using dynamic contrast-enhanced magnetic resonance imaging (DCEMRI) and outcomes of hepatocellular carcinoma (HCC) receiving radiotherapy with or without concomitant thalidomide. Methods: DCEMRI was performed in advanced HCC patients undergoing radiotherapy with or without concomitant thalidomide. Initial first-pass enhancement slopes (slope) and peak enhancement ratios (peak) were measured over an operator-defined region of interest over tumor and non-tumor liver parenchyma. The perfusion parameters were correlated with clinical outcomes. The study was registered with ClinicalTrials.gov. (identifier NCT00155272). Results: Forty-three patients were evaluable. There were 18 partial responses (PRs), 5 minimal responses (MRs), 17 stable diseases (SDs), and 3 progressive diseases (PDs). Baseline perfusion parameters as well as slope at 14?days of radiotherapy were higher in patients with PR or MR compared to SD or PD (0.81?±?0.29 vs. 0.49?±?0.34, p?
SDGs
Other Subjects
angiogenesis inhibitor; contrast medium; gadodiamide; gadolinium pentetate; thalidomide; aged; Carcinoma, Hepatocellular; clinical trial; disease free survival; female; human; Liver Neoplasms; male; multimodality cancer therapy; nuclear magnetic resonance imaging; phase 2 clinical trial; procedures; signal processing; survival rate; treatment outcome; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Media; Disease-Free Survival; Female; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Signal Processing, Computer-Assisted; Survival Rate; Thalidomide; Treatment Outcome
Type
journal article